Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

周二，美银证券分析师重申对Vertex股票 (NASDAQ: VRTX)的买入评级，并维持567.00美元的目标价。Vertex是生物技术行业的重要参与者，市值达1144亿美元。根据 InvestingPro 数据，分析师对Vertex的目标价范围从330美元到621美元不等，目前股价为445.43美元。此决定是在Vera ...

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment -- and that’s set to continue thanks to the ...

An entrepreneur rolled out his prototype solar-powered car, named INTI, after the Inca sun god. But will solar cars heat up ...

首先，2020年Vertex与另外一家AAV基因治疗公司Affinia ...

UBS analyst Eliana Merle reaffirmed a Buy rating and a $582 price target for Vertex Pharmaceuticals, praising the adoption of ...

Eli Lilly has reached a deal to acquire SiteOne Therapeutics that would give it control of a non-opioid pain drug that would ...

Tasmea (ASX:TEA) has executed a share purchase agreement to acquire electrical services company Vertex Group.

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion. Analysts surveyed by Visible Alpha were looking for $4.19 and $2.83 billion, ...

This was the stock's second consecutive day of gains.